Preclinical evaluation of 89Zr-labeled human antitransferrin receptor monoclonal antibody as a PET probe using a pancreatic cancer mouse model

Nuclear Medicine Communications

Volumn 36, Issue 3, 2015, Pages 286-294

  Sugyo, Aya ^a   Tsuji, Atsushi B ^a   Sudo, Hitomi ^a   Nagatsu, Kotaro ^a   Koizumi, Mitsuru ^b   Ukai, Yoshinori ^c   Kurosawa, Gene ^d   Zhang, Ming Rong ^a   Kurosawa, Yoshikazu ^a   Saga, Tsuneo ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b Cancer Institute Hospital   (Japan)

^c Perseus Proteomics   (Japan)

^d FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

immuno PET; mouse model; noninvasive imaging; pancreatic cancer; transferrin receptor

Indexed keywords

HUMAN MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TSP A01 ZR 89; MONOCLONAL ANTIBODY TSP A02; MONOCLONAL ANTIBODY TSP A03; MONOCLONAL ANTIBODY TSP A04; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY; RADIOISOTOPE; ZIRCONIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; COMPETITIVE INHIBITION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; INTERNALIZATION; ISOTOPE LABELING; MALE; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PANCREAS CANCER; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; RADIOCHEMISTRY; ANIMAL; CELL TRANSFORMATION; DIAGNOSTIC USE; DISEASE MODEL; GENE EXPRESSION REGULATION; IMMUNOLOGY; METABOLISM; PANCREAS TUMOR; PATHOLOGY; PROCEDURES; SCINTISCANNING; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ISOTOPE LABELING; MICE; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; RECEPTORS, TRANSFERRIN; TISSUE DISTRIBUTION; ZIRCONIUM;

EID: 84922399945     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0000000000000245     Document Type: Article

References (40)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64:9-29
2. Boyle P, Levin B, International Agency for Research on Cancer. World cancer report 2008. Lyon: World Health Organization; 2008
3. EVans J, Chapple A, Salisbury H, Corrie P, Ziebland S. It cant be very important because it comes and goes-patients accounts of intermittent symptoms preceding a pancreatic cancer diagnosis: a qualitative study. BMJ Open 2014; 4:e004215
4. Neckers LM, Trepel JB. Transferrin receptor expression and the control of cell growth. Cancer Invest 1986; 4:461-470
5. Lesley JF, Schulte RJ. Inhibition of cell growth by monoclonal anti-transferrin receptor antibodies. Mol Cell Biol 1985; 5:1814-1821
6. Gatter KC, Brown G, Trowbridge IS, Woolston RE, Mason DY. Transferrin receptors in human tissues: their distribution and possible clinical releVance. J Clin Pathol 1983; 36:539-545
7. Panaccio M, Zalcberg JR, Thompson CH, Leyden MJ, SulliVan JR, Lichtenstein M, McKenzie IF. Heterogeneity of the human transferrin receptor and use of anti-transferrin receptor antibodies to detect tumours in vivo. Immunol Cell Biol 1987; 65 (Pt 6):461-472
8. Daniels TR, Delgado T, Rodriguez JA, Helguera G, Penichet ML. The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol 2006; 121:144-158
9. Ryschich E, Huszty G, Knaebel HP, Hartel M, Büchler MW, Schmidt J. Transferrin receptor is a marker of malignant phenotype in human pancreatic cancer and in neuroendocrine carcinoma of the pancreas. Eur J Cancer 2004; 40:1418-1422
10. Daniels TR, Delgado T, Helguera G, Penichet ML. The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin Immunol 2006; 121:159-176
11. Daniels TR, Bernabeu E, Rodrguez JA, Patel S, Kozman M, Chiappetta DA, et al. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta 2012; 1820:291-317
12. Kurosawa G, Akahori Y, Morita M, Sumitomo M, Sato N, Muramatsu C, et al. Comprehensive screening for antigens overexpressed on carcinomas via isolation of human mAbs that may be therapeutic. Proc Natl Acad Sci USA 2008; 105:7287-7292
13. Kurosawa G, Sumitomo M, Ukai Y, Subere J, Muramatsu C, Eguchi K, et al. Selection and analysis of anti-cancer antibodies for cancer therapy obtained from antibody phage library. Cancer Sci 2011; 102:175-181
14. Sephton RG, Hodgson GS, De Abrew S, Harris AW. Ga-67 and Fe-59 distributions in mice. J Nucl Med 1978; 19:930-935
15. Levitt RG, Biello DR, Sagel SS, Stanley RJ, Aronberg DJ, Robinson ML, Siegel BA. Computed tomography and 67Ga citrate radionuclide imaging for evaluating suspected abdominal abscess. Am J Roentgenol 1979; 132:529-534
16. Vallabhajosula SR, Harwig JF, Wolf W. The mechanism of tumor localization of gallium-67 citrate: role of transferrin binding and effect of tumor pH. Int J Nucl Med Biol 1981; 8:363-370
17. Weiner RE. The mechanism of 67Ga localization in malignant disease. Nucl Med Biol 1996; 23:745-751
18. Holland JP, EVans MJ, Rice SL, Wongvipat J, Sawyers CL, Lewis JS. Annotating MYC status with 89Zr-transferrin imaging. Nat Med 2012; 18:1586-1591
19. Saga T, Endo K, Akiyama T, Sakahara H, Koizumi M, Watanabe Y, et al. Scintigraphic detection of overexpressed c-erbB-2 protooncogene products by a class-switched murine anti-c-erbB-2 protein monoclonal antibody. Cancer Res 1991; 51:990-994
20. Sogawa C, Tsuji AB, Sudo H, Sugyo A, Yoshida C, Odaka K, et al. C-kittargeted imaging of gastrointestinal stromal tumor using radiolabeled anti-ckit monoclonal antibody in a mouse tumor model. Nucl Med Biol 2010; 37:179-187
21. Sudo H, Tsuji AB, Sugyo A, Ogawa Y, Sagara M, Saga T. ZDHHC8 knockdown enhances radiosensitivity and suppresses tumor growth in a mesothelioma mouse model. Cancer Sci 2012; 103:203-209
22. Sugyo A, Tsuji AB, Sudo H, Nagatsu K, Koizumi M, Ukai Y, et al. Evaluation of (89)Zr-labeled human anti-CD147 monoclonal antibody as a positron emission tomography probe in a mouse model of pancreatic cancer. PLoS One 2013; 8:e61230
23. Perk LR, Vosjan MJ, Visser GW, Budde M, Jurek P, Kiefer GE, Van Dongen GA. p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. Eur J Nucl Med Mol Imaging 2010; 37:250-259
24. Nagatsu K, Suzuki H, Fukada M, Minegishi K, Tsuji A, Fukumura T. An alumina ceramic target vessel for the remote production of metallic radionuclides by in situ target dissolution. Nucl Med Biol 2012; 39:1281-1285
25. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984; 72:77-89
26. Yokoyama A, Ohmomo Y, Horiuchi K, Saji H, Tanaka H, Yamamoto K, et al. Deferoxamine, a promising bifunctional chelating agent for labeling proteins with gallium: Ga-67 DF-HSA: concise communication. J Nucl Med 1982; 23:909-914
27. Govindan SV, Michel RB, Griffiths GL, Goldenberg DM, Mattes MJ. Deferoxamine as a chelator for 67Ga in the preparation of antibody conjugates. Nucl Med Biol 2005; 32:513-519
28. Vosjan MJ, Perk LR, Visser GW, Budde M, Jurek P, Kiefer GE, Van Dongen GA. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat Protoc 2010; 5:739-743
29. Holland JP, Divilov V, Bander NH, Smith-Jones PM, Larson SM, Lewis JS. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med 2010; 51:1293-1300
30. Perk LR, Visser GW, Vosjan MJ, Stigter-Van Walsum M, Tijink BM, Leemans CR, Van Dongen GA. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. J Nucl Med 2005; 46:1898-1906
31. Zalutsky MR, Colcher D, Kaplan WD, Kufe DW. Radioiodinated B6.2 monoclonal antibody: further characterization of a potential radiopharmaceutical for the identification of breast tumors. Int J Nucl Med Biol 1985; 12:227-233
32. Arano Y, Mukai T, Uezono T, Wakisaka K, Motonari H, Akizawa H, et al. A biological method to evaluate bifunctional chelating agents to label antibodies with metallic radionuclides. J Nucl Med 1994; 35:890-898
33. Franano FN, Edwards WB, Welch MJ, Duncan JR. Metabolism of receptor targeted 111In-DTPA-glycoproteins: identification of 111In-DTPA-epsilonlysine as the primary metabolic and excretory product. Nucl Med Biol 1994; 21:1023-1034
34. Geissler F, Anderson SK, Venkatesan P, Press O. Intracellular catabolism of radiolabeled anti-mu antibodies by malignant B-cells. Cancer Res 1992; 52:2907-2915
35. Verel I, Visser GW, Boellaard R, Boerman OC, Van Eerd J, Snow GB, et al. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice. J Nucl Med 2003; 44:1663-1670
36. Nayak TK, Garmestani K, Milenic DE, Brechbiel MW. PET and MRI of metastatic peritoneal and pulmonary colorectal cancer in mice with human epidermal growth factor receptor 1-targeted 89Zr-labeled panitumumab. J Nucl Med 2012; 53:113-120
37. Fischer G, Seibold U, Schirrmacher R, Wngler B, Wngler C. (89)Zr, a radiometal nuclide with high potential for molecular imaging with PET: chemistry, applications and remaining challenges. Molecules 2013; 18:6469-6490
38. Trowbridge IS, Lopez F. Monoclonal antibody to transferrin receptor blocks transferrin binding and inhibits human tumor cell growth in vitro. Proc Natl Acad Sci USA 1982; 79:1175-1179
39. Wrba F, Ritzinger E, Reiner A, Holzner JH. Transferrin receptor (TrfR) expression in breast carcinoma and its possible relationship to prognosis. An immunohistochemical study. Virchows Arch A Pathol Anat Histopathol 1986; 410:69-73
40. Niitsu Y, Kohgo Y, Nishisato T, Kondo H, Kato J, Urushizaki Y, Urushizaki I. Transferrin receptors in human cancerous tissues. Tohoku J Exp Med 1987; 153:239-243